

The research commercialisation office of the University of Oxford, previously called **Isis Innovation**, has been renamed **Oxford University Innovation**

All documents and other materials will be updated accordingly. In the meantime the remaining content of this Isis Innovation document is still valid.

URLs beginning <u>www.isis-innovation.com/</u>... are automatically redirected to our new domain, <u>www.innovation.ox.ac.uk/</u>...

Phone numbers and email addresses for individual members of staff are unchanged

Email : enquiries@innovation.ox.ac.uk



Beyond Blood Glucose/HbA1c: Measuring the Patient's Perspective of the Benefits of Diabetes Interventions

Dr. Keith Meadows – DHP Author, Founder – DHP February 4th, 2016



Today's Webinar Host





Dr. Keith Meadows, BA (Hons), PhD, CMRS


Founder/Director -DHP Research & Consultancy Ltd.

DHP Screening Tool Author -The Diabetes Health Profile (DHP)

POST-EVENT QUESTIONS FOR THE HOST? Email: <u>kmeadows@dhpresearch.com</u>



Global Diabetes Impact – Infographic






Diabetes in the U.K.

UK Diagnosed



Diabetes type



Financial costs






52% Deaths due to cardiovascular disease

21% Type 1 Deaths due to kidney disease

70% Of people die within 5 years of an amputation



Diabetes in the U.K.



In 2011, one in every 400 to 600 children were diagnosed with diabetes...



The Psychological Impact of Living with Diabetes

The facts



according to Diabetes UK, **people with**

diabetes are twice as likely to

...and the risk is higher for women than for man

"Yet there is little routine psychological support for people with diabetes."

Diabetes UK



The Psychological Impact of Living with Diabetes

ANXIETY

aggression

Denial

Eating problems

Treatment nonadherence

POOR QUALITY OF LIFE

disruption to social and professional life



Diabetes-specific PROs in a Real World Setting

- Efficacy of treatment
- Need for real world data driven by changing regulatory environment, drug safety and efficacy
- Identification of factors leading to treatment nonadherence and drug ineffectiveness
- Enables clinicians to tailor treatment regimens based on patient needs
- Increase treatment adherence as part of patient support programmes



The Diabetes Health Profile

The Diabetes Health Profile (DHP),

a multidimensional, diabetes-specific (T1 and T2), patient self-report outcome measure of the psychological and behavioural impact of patients living with diabetes.






Provisional development of the DHP

- A review of the literature.
- In-depth interviews with 45 diabetes patients analysed using a thematic approach.
- Examination of existing instruments of psychosocial functioning.
- Discussions with health care professionals (diabetologists), Diabetes Specialist Nurse (DSN) and dieticians.









Provisional development of the DHP

4500 T1 & T1 Diabetes Patients





Conceptual Framework for the DHP-1 and DHP-18







	DHP-1	DHP-18	
Administer	Type 1 Diabetes Individuals 16 years and older	Type 1 Diabetes Individuals 16 years and older	
Reading Level	6th grade	6th grade	
Scales (No of items)	Psychological distress (14) Barriers to activity (13) Disinhibited eating (5)	Psychological distress (6) Barriers to activity (7) Disinhibited eating (5)	
Response options	Four-point adjectival scales	Four-point adjectival scales	
Formats	Paper-and-pencil, interview	Paper-and-pencil interview, electronic hand held, tablet, IVR, web	
Scoring	Items scores 0–3 in each dimension summed & transformed to produce score 0 (no dysfunction to 100)	Items scores 0–3 in each dimension summed & transformed to produce score 0 (no dysfunction to 100)	
Completion time	9-12 minutes	5–6 minutes	
Research & Resources	DHP manual, research support, training and workshops*	DHP manual, research support, training and workshops**	
FAQs	Yes (see below)	Yes (see below)	






Development of the Diabetes Health Profile

Appraisal component	DHP-1	DHP-18
Reproducibility	*	*
Internal consistency	**	***
Content validity	***	***
Construct validity	***	***
Responsiveness	*	*
Interpretability	*	*
MID	0	*
Floor/ceiling effects	***	***
Acceptability	**	**
Feasibility	0	0
Cost utility analysis	0	*

0 Not reported 🛛 ★ Some limited evidence 🔸 ★ Some good evidence in favour 🔸 ★★ Good evidence in favour



Previous and Current Users of the DHP





Instituts thématiques

Inserm

Typical Applications of the DHP

- Measure improvement or decline in the psychological and behavioural functioning of patients
- Screen for unmet need
- **Demonstrate** drug efficacy (perceived value)
- Assess treatment effectiveness
- Assess intervention programmes
- Enhance treatment adherence by improving communication between you and your patients





Translations

- Bulgarian
- Croatian
- Czech
- Danish
- Dutch
- Dutch (Belgium)
- English (Canada)
- English (USA)
- Finish
- French
- French (Belgium)
- French (Canada)
- French (Swiss)
- German

- German (Austria)
- German (Swiss)
- Hungarian
- Italian
- Italian (Swiss)
- Mandarin
- Norwegian
- Polish
- Romanian
- Turkish (German)
- Slovak
- Slovenian
- Spanish
- Spanish (USA)
- Swedish



User Guide: The DHP Instrument














DHP Response Rates & Data quality


Pilot study of patient reported outcome measures (PROMs) in primary care

UK Department of Health



DHP-18 % Response Rates






Pilot study of patient reported outcome measures (PROMs) in primary care. *Report to the Department of Health.* Michele Peters Department of Public Health University of Oxford 2013.






Response rates by LTC



Pilot study of patient reported outcome measures (PROMs) in primary care. *Report to the Department of Health.* Michele Peters Department of Public Health University of Oxford 2013.



% of missing data for the EQ5D and DHP



Pilot study of patient reported outcome measures (PROMs) in primary care. *Report to the Department of Health*. Michele Peters Department of Public Health University of Oxford 2013.









DHP-18 Domain scores by comorbidity

N=1802 (45% RR) TI & T2 diabetes general practice patients





Living with diabetes: Interpreting the Diabetes Health Profile




Factors associated with psychological and behavioural functioning in people with type 2 diabetes living in France.Stephanie Boini, Marie-Line Erpelding et al.Health Quality of Life Outcomes 2010, 8:124





Getting an In-Depth Look at Diabetes with the DHP-18







Recent Developments





Interpreting the Diabetes Health Profile

The minimally important difference (MID) is the smallest score difference on the Diabetes Health Profile that represents the minimal clinically significant difference.

Investigating the minimally important difference of the Diabetes Health Profile (DHP-18) and the EQ-5D and SF-6D in a UK diabetes mellitus population. Mulhern B and Meadows K. Health 5: 1045-1054,2013





Interpreting the Diabetes Health Profile

A longitudinal dataset from a UK communitybased postal survey carried out in one health authority area

- 1092 respondents with a reported diagnosis of Type 1
- Type 2 (n = 999) diabetes...

who fully completed the EQ-5D, SF-6D and DHP-18 at both baseline and 1-year follow-up.

Investigating the minimally important difference of the Diabetes Health Profile (DHP-18) and the EQ-5D and SF-6D in a UK diabetes mellitus population. Mulhern B and Meadows K. Health 5: 1045-1054,2013



Interpreting the Diabetes Health Profile




The required MID change in score for the DHP-18 domains



Investigating the minimally important difference of the Diabetes Health Profile (DHP-18) and the EQ-5D and SF-6D in a UK diabetes mellitus population. Mulhern B and Meadows K. Health 5: 1045-1054,2013



Development of an e-version of the DHP







"An Author pre-approved instrument qualifies the migrated instrument to the author's level of quality and expectation. - Elan Josielewski (Mapi Group)

Having followed good practices in instrument migration, it is considered that an Author pre-approved instrument would, with reasonable testing (in line with industry guidelines), demonstrate equivalence".

- David Churchman (iOutcomes)




Advantages of an eDHP

- Facility to apply computerised adaptive scoring
- Preference-based scoring using three-item DHP currently being derived from the DHP-18
- Collection of symptom events etc. on the same electronic platform
- Real-time DHP-18 scores benchmarked against age, gender, diabetes type, acute complications e.g. hypoglycaemic episodes



Integration of the DHP-18 into holistic assessment of needs programme for Type 1 and Type 2 patients.





DHP preference-based measure

- DHP-3 & DHP5 will be able to estimate QALYs for the assessment of diabetes specific interventions in existing datasets or in future trials that include the DHP-18 or DHP-1
- The DHP-5D be able to estimate QALYs in data or trials where the DHP-1 and SF-36 are included





- **Developed** with significant patient input
- A clearly defined conceptual framework of the measurement model which conforms to the FDA Final guidance for Industry
- The measurement of dysfunctional eating behaviour which despite its importance in the management of diabetes is absent in other scales
- **Content** No hypothetical questions relates to real life experiences which respondents identify and engage with
- Suitable for use in range of research settings including population surveys, phase III and real world data collection
- Minimum Important Difference (MID) Values available
- Now available as an eDHP Author approved



Thank You for Attending!



For more information, email us or visit our website:

- info@dhpresearch.com
- www.diabetesprofile.com

For licensing enquiries, email or call the following:

- <u>healthoutcomes@innovation.ox.ac.uk</u>
- T: +44 (0)1865 614417



